BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hagemann UB, Wickstroem K, Hammer S, Bjerke RM, Zitzmann-Kolbe S, Ryan OB, Karlsson J, Scholz A, Hennekes H, Mumberg D, Cuthbertson AS. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy. Cancer Biother Radiopharm 2020;35:497-510. [PMID: 32255671 DOI: 10.1089/cbr.2020.3568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. J Med Chem 2021;64:12723-37. [PMID: 34428039 DOI: 10.1021/acs.jmedchem.1c00762] [Reference Citation Analysis]
2 Wengner AM, Scholz A, Haendler B. Targeting DNA Damage Response in Prostate and Breast Cancer. Int J Mol Sci 2020;21:E8273. [PMID: 33158305 DOI: 10.3390/ijms21218273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Nelson BJ, Andersson JD, Wuest F. Radiolanthanum: Promising theranostic radionuclides for PET, alpha, and Auger-Meitner therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.04.005] [Reference Citation Analysis]
4 Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021;13:906. [PMID: 34207408 DOI: 10.3390/pharmaceutics13060906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Pijeira MSO, Viltres H, Kozempel J, Sakmár M, Vlk M, İlem-Özdemir D, Ekinci M, Srinivasan S, Rajabzadeh AR, Ricci-Junior E, Alencar LMR, Al Qahtani M, Santos-Oliveira R. Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology. EJNMMI Radiopharm Chem 2022;7:8. [PMID: 35467307 DOI: 10.1186/s41181-022-00161-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sharma S, Baral M, Kanungo BK. Recent advances in therapeutical applications of the versatile hydroxypyridinone chelators. J Incl Phenom Macrocycl Chem. [DOI: 10.1007/s10847-021-01114-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 2020;19:589-608. [PMID: 32728208 DOI: 10.1038/s41573-020-0073-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 27.5] [Reference Citation Analysis]
8 Roy J, Jagoda EM, Basuli F, Vasalatiy O, Phelps TE, Wong K, Ton AT, Hagemann UB, Cuthbertson AS, Cole PE, Hassan R, Choyke PL, Lin FI. In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab. Cancer Biother Radiopharm 2021;36:316-25. [PMID: 34014767 DOI: 10.1089/cbr.2020.4492] [Reference Citation Analysis]
9 Herrero Álvarez N, Bauer D, Hernández-Gil J, Lewis JS. Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. ChemMedChem 2021. [PMID: 33792195 DOI: 10.1002/cmdc.202100135] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zhou X, Dong L, Shen L. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals. Molecules 2021;26:6997. [PMID: 34834087 DOI: 10.3390/molecules26226997] [Reference Citation Analysis]
11 Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L, Berndt S, Zitzmann-Kolbe S, Kamfenkel C, Stargard S, Hammer S, Jørgensen JS, Jackerott M, Nielsen CH, Schatz CA, Hennekes H, Karlsson J, Cuthbertson AS, Mumberg D, Hagemann UB. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. J Immunother Cancer 2021;9:e002387. [PMID: 34615703 DOI: 10.1136/jitc-2021-002387] [Reference Citation Analysis]
12 Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH. Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel) 2021;13:779. [PMID: 33668474 DOI: 10.3390/cancers13040779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]